Evidence map›Paper›PMID 23142217›Full record

ArticleCancer letters2013

MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3.

Xuguang Zheng, Michael Chopp, Yong Lu, Benjamin Buller, Feng Jiang

Abstract read
In one paragraph

Article in Cancer letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 1 synthesis or guideline pooled it, 169 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xuguang ZhengDepartment of Neurology, Henry Ford Hospital, Detroit, MI, USA.
Michael Chopp
Yong Lu
Benjamin Buller
Feng Jiang
Henry Ford Hospital · US

Funding

ADAM 17 and glioma-tumor progression and treatmentR01CA129446 · NCI · HENRY FORD HEALTH SYSTEM · PI JIANG, FENG · 2009 to 2013
$1.5M
NCI NIH HHS R01 CA129446
6 · The paper itself

Abstract

We tested invasion and angiogenesis related mRNA expression and miRNA profiles of glioma. Genes with mRNA expression that changed significantly were selected to predict possible miRNAs that regulate mRNA expression, and were then matched with miRNA results. NRP-2 with the matching miRNA miR-15b, and MMP-3 with the matching miRNA miR-152 were selected for further study. Luciferase activity assay confirmed that miR-15b and miR-152 attenuate expression of NRP-2 and MMP-3 protein by binding to NRP-2 and MMP-3 transcript, respectively. In vitro invasion assay data showed that miR-15b and miR-152 significantly decreased 9L cell invasiveness. In vitro tube formation assay data showed that miR-15b reduced tube formation. A preliminary pathway study indicated that miR-15b and miR-152 deactivated the MEK-ERK pathway via NRP-2 and MMP-3 in 9L cells, respectively.

Indexed as

AnimalsAstrocytesCell Line, TumorCell MovementCoculture TechniquesEndothelial CellsExtracellular Signal-Regulated MAP KinasesGene Expression Regulation, NeoplasticGliomaMAP Kinase Signaling SystemMatrix Metalloproteinase 3MicroRNAsNeoplasm InvasivenessNeovascularization, PathologicNeuropilin-2RatsExtracellular Signal-Regulated MAP KinasesMatrix Metalloproteinase 3MicroRNAsMIRN152 microRNA, ratmirn15 microRNA, ratNeuropilin-2RNA, Messenger

Identifiers

PMID23142217
PMCPMC3553580
OpenAlexW2105325479

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.